Tag Archives: David Satcher

Today is Give Kids a Smile Day!

Today is the 13th anniversary of the American Dental Association‘s Give Kids a Smile Day program. Aimed at raising awareness and helping to address the high level of oral disease in kids, especially in underserved communities, this program enables volunteers to provide free dental care to those in need and urges policymakers to increase funding for children’s oral health.

Dental caries, referred to as a “silent epidemic” by former U.S. Surgeon General David Satcher, are the cause of many otherwise preventable health issues. Investing in comprehensive oral health care for children will result in fewer instances of dental caries in adulthood. Studies have shown that increased funding for combating oral health conditions results in fewer emergency room visits and lower health care costs across the board.

To help highlight the importance of dental health research, we have partnered with Colgate-Palmolive and the Children’s Dental Health Project to create the fact sheet:

Investment in Research Improves Lives and Saves Money Facts about: Children’s Dental Health Research.ChildrensDentalHealthResearch

“Addressing preventable disease is the norm in today’s health care system. It is the most effective way to reduce costs and improve health. This is no different for oral disease. Working together, industry and its partners can enhance the prevention and treatment of oral disease through the development and testing of new treatments that will improve oral health, overall health and quality of life for all.” – Dr. Foti Panagakos, DMD, Ph.D, global director of scientific affairs, Colgate-Palmolive

A Weekly Advocacy Message from Mary Woolley: Finally, tax policy is on the agenda

Dear Research Advocate:

What will determine the speed and scope of medical progress in the years to come? There is more to it than the essential ingredients of money and brainpower.

Sound tax policy is essential if we are to propel medical progress.

Yesterday, Rep. Dave Camp (R-MI-04), chairman of the House Ways and Means Committee, introduced a comprehensive tax reform bill. While the prospects for passage during this election year are — to put a positive spin on it — uncertain, Congressman Camp laid down the gauntlet for much-needed tax and entitlement reform, and he also proposed making the R&D tax credit permanent. Uncertainty surrounding future access to the R&D tax credit has reduced its power to drive private sector R&D investment. While the Camp bill does not contain the ideal package of changes needed to optimize the usefulness of the credit, and in fact contains some potential setbacks, his decision to support making the R&D tax credit permanent sets the stage for finally achieving this long-standing goal.

Scientists, physicians and patients must all work to increase clinical trial participation.

In a recent Washington Post op-ed, a personal hero of mine, former Surgeon General and CDC Director David Satcher, MD, discusses the importance of African-Americans contributing to medical progress by participating in clinical research. Using Alzheimer’s disease as a lens, he argues that adequate research funding is not the only imperative; individuals must be willing to volunteer for clinical trials. Participation is especially valuable for racial and ethnic groups who have much to gain as health disparities persist, but who understandably remember mistreatment in trials in the past. Polling commissioned by Research!America has affirmed this lack of trust but also, importantly, has revealed that African-Americans in particular say they want to help others by participating in trials. We also learned from our polls that most Americans, across all demographics, look to their physicians to be the touchpoint for learning about clinical trial participation.

Improved scientist engagement with the public and policy makers is essential.

Medical research stands a better chance of becoming a higher national priority if people can connect meaningfully to scientists. As Alan Alda said at the annual AAAS meeting last week, and in an interview with Claudia Dreifus in The New York Times, “How are scientists going to get money from policy makers if our leaders and legislators can’t understand what they do?” He and his colleagues at the Alan Alda Center for Communicating Science at Stony Brook use of the some of the same approaches we do to help the science community connect with non-scientists in ways that can truly move mountains. Alda adds a passion for science with dramatic talent for a skill set we can all learn from.

Media attention — old school and new school — is key.

Both traditional and social media play a role in the fate of U.S. medical progress because of their ability to call public and policy maker attention to possibilities and stumbling blocks. Research!America and the Pancreatic Cancer Action Network hosted a media luncheon today to discuss the challenges involved in turning cancer, in all its insidious forms, into a manageable chronic condition. It was reinforced to us that journalists’ questions are good markers of questions the public in general are raising; it’s important for scientists and advocates to listen and respond. Sometimes we fall into the pattern of just repeating our own messages louder and louder, but we should instead step back and listen to the sometimes-challenging questions being raised by media as they seek to inform the public. All of us who care about the future of research for health should seek out opportunities to engage with journalists. Contact us for suggestions on how to get started!

Sincerely,

Mary Woolley

More African Americans need to participate in clinical trials

Excerpt of an op-ed by David Satcher, MD, PhD, honorary chairman of the African American Network Against Alzheimer’s, former U.S. surgeon general and Research!America’s 2007 Raymond and Beverly Sackler Award for Sustained National Leadership award winner, published in The Washington Post.

DavidSatcher1Every February our society measures its progress in the march toward equality as part of Black History Month. But seldom do we discuss inequality in health, an injustice that continues to plague African Americans.

A whole host of health disparities remains unaddressed, including Alz­heimer’s — a disease that African Americans are two to three times more likely to develop than non-Hispanic whites. This disparity is rooted as much in our cultural heritage as in our genes.

For years, studies have found that African Americans have a profound mistrust of doctors and scientists. Consequently, we participate in clinical trials at far lower rates than other ethnic groups, which helps to perpetuate the sort of disparities seen with diseases such as Alzheimer’s. This fear of clinical trials dates to a dark chapter in our shared history: the Tuskegee syphilis experiments.

The Tuskegee study was an infamous clinical experiment in which researchers and the U.S. Public Health Service led African American men with syphilis to believe that they were receiving free medical care while, unbeknown to them, they were being left untreated so scientists could study the effects of prolonged syphilis. After the Associated Press exposed the truth, sparking a public outcry, the U.S. government ended the study in 1972, 40 years after it began.

The 1974 National Research Act set new guidelines for the use of humans in clinical studies. In 1997, the Clinton administration worked with higher education institutions to usher in new training requirements and ethical standards for physicians, researchers and medical students as part of an official apology President Bill Clinton issued on behalf of the nation to the victims of the experiments. While these standards go a long way toward helping to prevent future such experiments, much damage was already done among African Americans.

Read the full op-ed here.